BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015; 7(3): 566-574 [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Qu L, Zhang H, Yang Y, Yang G, Xin H, Ling C. Corosolic acid analogue, a natural triterpenoid saponin, induces apoptosis on human hepatocarcinoma cells through mitochondrial pathway in vitro. Pharmaceutical Biology 2016;54:1445-57. [DOI: 10.3109/13880209.2015.1104699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
2 Ge S, Xu Y, Wang H, Sun Y, Tian X, Cao Z, Lin X, Xu J, Wang Q. Downregulation of esophageal cancer-related gene 4 promotes proliferation and migration of hepatocellular carcinoma. Oncol Lett 2017;14:3689-96. [PMID: 28927132 DOI: 10.3892/ol.2017.6616] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
3 Ji S, Ma Y, Xing X, Ge B, Li Y, Xu X, Song J, Xiao M, Gao F, Jiang W, Fang C, Wang X. Suppression of CD13 Enhances the Cytotoxic Effect of Chemotherapeutic Drugs in Hepatocellular Carcinoma Cells. Front Pharmacol 2021;12:660377. [PMID: 34045966 DOI: 10.3389/fphar.2021.660377] [Reference Citation Analysis]
4 张竹青, 卢书明. MicroRNAs在肝细胞肝癌中作用的研究进展. 世界华人消化杂志 2015; 23(30): 4844-4851 [DOI: 10.11569/wcjd.v23.i30.4844] [Reference Citation Analysis]
5 Li GJ, Chen QY, Harrison TJ, Wang XY, Hu LP, Yang QL, Li KW, Fang ZL. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study. Cancer Biomark 2017;18:241-8. [PMID: 28085009 DOI: 10.3233/CBM-160131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Hyun SH, Eo JS, Song BI, Lee JW, Na SJ, Hong IK, Oh JK, Chung YA, Kim TS, Yun M. Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging. 2018;45:720-726. [PMID: 29167923 DOI: 10.1007/s00259-017-3880-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
7 Zhang W, Sun H, Shi X, Wang H, Cui C, Xiao F, Wu C, Guo X, Wang L. SENP1 regulates hepatocyte growth factor-induced migration and epithelial-mesenchymal transition of hepatocellular carcinoma. Tumour Biol. 2016;37:7741-7748. [PMID: 26695141 DOI: 10.1007/s13277-015-4406-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
8 Zhang J, Fang C, Qu M, Wu H, Wang X, Zhang H, Ma H, Zhang Z, Huang Y, Shi L, Liang S, Gao Z, Song W, Wang X. CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents. Front Pharmacol 2018;9:1042. [PMID: 30258365 DOI: 10.3389/fphar.2018.01042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
9 Shin SK, Kim YS, Choi SJ, Shim YS, Jung DH, Kwon OS, Choi DJ, Kim JH. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article. Medicine (Baltimore) 2017;96:e7278. [PMID: 28723741 DOI: 10.1097/MD.0000000000007278] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Reference Citation Analysis]
11 Azad I, Jafri A, Khan T, Akhter Y, Arshad M, Hassan F, Ahmad N, Khan AR, Nasibullah M. Evaluation of pyrrole-2,3-dicarboxylate derivatives: Synthesis, DFT analysis, molecular docking, virtual screening and in vitro anti-hepatic cancer study. Journal of Molecular Structure 2019;1176:314-34. [DOI: 10.1016/j.molstruc.2018.08.049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
12 Jia M, Xiong Y, Li M, Mao Q. Corosolic Acid Inhibits Cancer Progress Through Inactivating YAP in Hepatocellular Carcinoma. Oncol Res 2020;28:371-83. [PMID: 32220262 DOI: 10.3727/096504020X15853075736554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Wei H, Yu X, Xue X, Liu H, Wang M, Li Y, Wang X, Ding H. Urotensin II receptor as a potential biomarker for the prognosis of hepatocellular carcinoma patients. Oncol Lett 2017;14:2749-56. [PMID: 28927036 DOI: 10.3892/ol.2017.6545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Qayyum A, Hwang KP, Stafford J, Verma A, Maru DM, Sandesh S, Sun J, Pestana RC, Avritscher R, Hassan MM, Amin H, Rashid A, Wistuba II, Ehman RL, Ma J, Kaseb AO. Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. J Immunother Cancer 2019;7:329. [PMID: 31779702 DOI: 10.1186/s40425-019-0766-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
15 Ventura Y, Carr BI, Kori I, Guerra V, Shibolet O. Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization. World J Gastroenterol 2018; 24(15): 1641-1649 [PMID: 29686471 DOI: 10.3748/wjg.v24.i15.1641] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
16 Wang Y, Chen CL, Pan QZ, Wu YY, Zhao JJ, Jiang SS, Chao J, Zhang XF, Zhang HX, Zhou ZQ, Tang Y, Huang XQ, Zhang JH, Xia JC. Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. Oncotarget 2016;7:6323-34. [PMID: 26575170 DOI: 10.18632/oncotarget.6319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
17 Ding H, Ye ZH, Wen DY, Huang XL, Zeng CM, Mo J, Jiang YQ, Li JJ, Cai XY, Yang H, Chen G. Downregulation of miR‑136‑5p in hepatocellular carcinoma and its clinicopathological significance. Mol Med Rep 2017;16:5393-405. [PMID: 28849100 DOI: 10.3892/mmr.2017.7275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 Lee JS, Lee HA, Jeon MY, Lim TS, Kim BK, Park JY, Kim DY, Ahn SH, Um SH, Han K, Seo YS, Kim SU. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. European Journal of Gastroenterology & Hepatology 2020;32:739-47. [DOI: 10.1097/meg.0000000000001585] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Bakr NM, Awad A, Moustafa EA, El-Gebaly AM. The association between interleukin-21 (rs2055979G/T) gene polymorphism and the risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus. J Cell Biochem 2019;120:18524-32. [PMID: 31237020 DOI: 10.1002/jcb.29174] [Reference Citation Analysis]
20 da Motta Girardi D, Correa TS, Crosara Teixeira M, Dos Santos Fernandes G. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. J Gastrointest Canc 2018;49:227-36. [DOI: 10.1007/s12029-018-0121-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
21 Sobotka L, Hinton A, Conteh L. Women receive more inpatient resections and ablations for hepatocellular carcinoma than men. World J Hepatol 2017; 9(36): 1346-1351 [PMID: 29359018 DOI: 10.4254/wjh.v9.i36.1346] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
22 Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World J Hepatol 2019; 11(1): 1-18 [PMID: 30705715 DOI: 10.4254/wjh.v11.i1.1] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 38.5] [Reference Citation Analysis]
23 Shen S, Sun CY, Du XJ, Li HJ, Liu Y, Xia JX, Zhu YH, Wang J. Co-delivery of platinum drug and siNotch1 with micelleplex for enhanced hepatocellular carcinoma therapy. Biomaterials. 2015;70:71-83. [PMID: 26302232 DOI: 10.1016/j.biomaterials.2015.08.026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
24 Ali MM, H Borai I, Ghanem HM, H Abdel-Halim A, Mousa FM. The prophylactic and therapeutic effects of Momordica charantia methanol extract through controlling different hallmarks of the hepatocarcinogenesis. Biomed Pharmacother 2018;98:491-8. [PMID: 29287196 DOI: 10.1016/j.biopha.2017.12.096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
25 Zhao Y, Wu H, Xing X, Ma Y, Ji S, Xu X, Zhao X, Wang S, Jiang W, Fang C, Zhang L, Yan F, Wang X. CD13 Induces Autophagy to Promote Hepatocellular Carcinoma Cell Chemoresistance Through the P38/Hsp27/CREB/ATG7 Pathway. J Pharmacol Exp Ther 2020;374:512-20. [PMID: 32571958 DOI: 10.1124/jpet.120.265637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Li Y, Zhang Y, Fang Q, Zhang X, Hou P, Wu H, Wang X. Radiomics analysis of [18F]FDG PET/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2021;48:2599-614. [PMID: 33416951 DOI: 10.1007/s00259-020-05119-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Sun ZP, Zhang J, Shi LH, Zhang XR, Duan Y, Xu WF, Dai G, Wang XJ. Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition. Biomed Pharmacother 2015;76:65-72. [PMID: 26653552 DOI: 10.1016/j.biopha.2015.10.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
28 Simoes CC, Thung SN, Fiel MI, Sung MW, Schwartz ME, Ward SC. Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Mod Pathol 2021;34:823-33. [PMID: 32989224 DOI: 10.1038/s41379-020-00679-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Yao J, Fu J, Liu Y, Qu W, Wang G, Yan Z. LncRNA CASC9 promotes proliferation, migration and inhibits apoptosis of hepatocellular carcinoma cells by down-regulating miR-424-5p. Ann Hepatol 2021;23:100297. [PMID: 33346094 DOI: 10.1016/j.aohep.2020.100297] [Reference Citation Analysis]
30 Wang Z, Huang Y, Tan L. Downregulation of lncRNA DANCR promotes osteogenic differentiation of periodontal ligament stem cells. BMC Dev Biol. 2020;20:2. [PMID: 31931700 DOI: 10.1186/s12861-019-0206-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]